PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
January 23, 2026Journal of Crohn s and Colitis

P1073Real-World Effectiveness, Symptomatic Improvement, and Safety of Upadacitinib in Patients With Moderate-to-Severe Ulcerative Colitis: Interim Findings From the PROFUNDUS Study

View Full Paper
Ask AI
Bookmark
Share

Authors

RPR PanaccioneMFMathurin FumeryDBDominik Bettenworth

Discussion

Loading...

Member takes

Overview

Open-label study evaluates symptomatic improvement and safety of upadacitinib in ulcerative colitis, suggesting favorable outcomes.

Key Points

  • This analysis examines the effectiveness and safety of upadacitinib in patients with moderate-to-severe ulcerative colitis.
  • Evaluated patients with moderate-to-severe UC initiating upadacitinib treatment.
  • Monitored clinical outcomes over 26 weeks, focusing on multiple endpoints.
  • Assessed treatment-emergent adverse events to evaluate safety.
  • At week 26, 81.8% achieved clinical response and 66.3% reached clinical remission.
  • 64.4% of corticosteroid users achieved corticosteroid-free response.
  • Adverse events were reported in 66% of treated patients, with few classified as serious.

Cite This Study

Panaccione et al. (2026) studied this question.

synapsesocial.com/papers/69731005c8125b09b0d1fb87https://doi.org/10.1093/ecco-jcc/jjaf231.1254
View Full Paper
Ask AI
Bookmark
Share